home / stock / fwbi / fwbi news

FWBI News and Press, First Wave BioPharma Inc. From 02/21/23

Stock Information
Company Name: First Wave BioPharma Inc.
Stock Symbol: FWBI
Market: NASDAQ
Menu
FWBI FWBI Quote FWBI Short FWBI News FWBI Articles FWBI Message Board
Get FWBI Alerts

News, Short Squeeze, Breakout and More Instantly...
FWBI - First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference

BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...
FWBI - First Wave BioPharma, Inc. (NASDAQ: FWBI) Featured in Coverage of the 35th Annual Roth Conference

First Wave BioPharma (NASDAQ: FWBI) is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company is currently advancing a therapeutic development pipeline with multiple clinical s...

FWBI - First Wave BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement

BOCA RATON, Fla., Feb. 07, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...

FWBI - First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

BOCA RATON, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...
FWBI - First Wave to start phase 2 trial of new formulation of adrulipase for pancreatic disorder

First Wave BioPharma ( NASDAQ: FWBI ) said it will start a phase 2 trial of an enteric microgranule delivery formulation of adrulipase to treat exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The company noted that U.S. Food and Drug Administration (FDA)...

FWBI - First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

BOCA RATON, Fla., Jan. 31, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...

FWBI - First Wave BioPharma to Present at the BIO CEO & Investor Conference

BOCA RATON, Fla., Jan. 30, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti...
FWBI - Why Is First Wave BioPharma (FWBI) Stock Up 30% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Many  Nasdaq stocks were in the red this morning, but not First Wave BioPharma (NASDAQ: FWBI ) stock. Indeed, First Wave shares were up substantially after the company announced an addition to its intellectual proper...

FWBI - First Wave surges ~30% on patent filing for adrulipase's delayed release formulation

First Wave BioPharma ( NASDAQ: FWBI ) said it filed a U.S. provisional patent application related to composition of matter improvements for enhancing adrulipase's delayed release profile. This filing adds to the intellectual property (IP) portfolio related to adrulipase, which in...

FWBI - First Wave BioPharma Announces Expansion of Adrulipase Intellectual Property Portfolio

BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointe...
Previous 10 Next 10